Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1. ELEVATE-45-201 is a Phase 1/2 MAD clinical study of ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping.

"We are pleased that after reviewing Cohort 1 data from our ELEVATE-45-201 study, the independent Data Monitoring Committee supports the initiation of Cohort 2 dosing at the increased dose of 10 mg/kg," said Natarajan Sethuraman, PhD, President of Research and Development at Entrada Therapeutics. "We look forward to sharing safety and early PK and dystrophin data from Cohort 1 of our ELEVATE-45-201 study in mid-2026. Importantly, with a dosing regimen of once every six weeks, ENTR-601-45 has the added potential to improve outcomes while decreasing the burden of treatment for people living with DMD who are exon 45 skipping amenable."

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.